Astrazeneca Share Discussion Threads

[riskonricky] 17/7/2022 10:07

Nobody D-dimmer than you m8

[jimarilo] 17/7/2022 09:29

big pHARMa is a crime syndicate keeping you ill is their business

The End of Germ Theory

[jimarilo] 17/7/2022 09:26

The jabs are poison

30.13 mins in .....my D-Dimmer blood clot test should have been at 100-200, but came in at 7000

Those that are denying the jab is poison are to afraid to take a D-Dimmer blood test ..no surprise there then

[dudishes] 15/7/2022 11:35

Waldron, yes sold GSK, got the gitters. AZN, two reasons, the buy in France and I think it's peaked for now.

I'll be back (maybe catch the divi)!

[montyhedge] 14/7/2022 15:22

One thing weak sterling good for FTSE 100 dollar earners, when converted back to sterling for dividends.But when the market like this the good bad and ugly all get hit.Astra, GSK, Hikma, Glencore etc etc.

[philanderer] 12/7/2022 11:10

Citigroup raises AstraZeneca price target to 13,000 (10,500) pence - 'buy'

[ozzywalker] 11/7/2022 14:29

Sold at 11,004 time will tell if it was the right decision, looking at SVT and ITRK. Good luck all

[waldron] 08/7/2022 17:35

Next dividend

Declaration date 03 Aug 2022 (Wed)

Ex-div date 11 Aug 2022 (Thu)

Pay date 12 Sep 2022 (Mon)

[waldron] 08/7/2022 17:29

Starting to look toppy perhaps

[waldron] 08/7/2022 17:23

thought you were keeping AZN Dud and sold GSK

[dudishes] 08/7/2022 17:03

I bailed today, held since 2009 and subsequent years.

If I get back to fitness, may invest again.

In all those years, never checked the divi?

I think 343% over 13yrs, not so bad.

Good luck

[diku] 06/7/2022 15:31

AZN paper is so rich...

[montyhedge] 06/7/2022 12:11

Pound going to 1.15 analysts reckon, great news for FTSE 100 dollar earners bigger profits and dividends when converted.Astra, GSK, Hikma, Glencore etc.

[waldron] 05/7/2022 08:47

AstraZeneca PLC said Tuesday that it is buying TeneoTwo, Inc. for up to $1.27 billion in a deal that strengthens its haematological cancer pipeline.

The pharmaceutical giant said it will make an upfront payment of $100 million upon closing of the deal. A further payment of up to $805 million will be made dependent upon research-and-development milestones being reached and extra payments of up to $360 million could be payable to TeneoTwo shareholders based upon commercial-related milestones.

Astra said the acquisition is expected to close in the third quarter of this year and that it doesn't impact financial guidance for the year.



Write to Ian Walker at [e-mail]



(END) Dow Jones Newswires

July 05, 2022 02:31 ET (06:31 GMT)

[ram376s] 04/7/2022 10:05

gdr popish

[adrian j boris] 01/7/2022 08:53

Oxford BioMedica PLC said Friday that it has signed an extended agreement with AstraZeneca UK Ltd. for the use of its facility to produce AstraZeneca's Covid-19 vaccine.

The U.K. gene and cell therapy group said the new three-year agreement makes the vaccines manufacturing facility Oxbox available to AstraZeneca on an as-needed basis beyond 2022.

The deal represents an expansion of the original deal between the two companies in September 2020, which was originally expected to be complete in the last quarter of 2022, it added.

The company added that the company expects to recognize an aggregate revenue of 30 million pounds ($36.5 million) in the current financial year from AstraZeneca for the batches already manufactured in the first half of 2022.



Write to Michael Susin at [e-mail]



(END) Dow Jones Newswires

July 01, 2022 02:56 ET (06:56 GMT)

[diku] 30/6/2022 09:02

This is bubble waiting to burst...think FTSE is artificially held up by AZN...

[barrenwuffet1] 29/6/2022 17:18

Time to sell do you reckon?

[steeplejack] 29/6/2022 16:35

52 week high.....all time high.

[the grumpy old men] 27/6/2022 08:13

AstraZeneca PLC said Monday that its Enhertu drug has been recommended for approval in the European Union for patients with breast cancer.

The pharmaceutical company said Enhertu has been recommended by the EU's Committee for Medicinal Products for Human Use as a monotherapy for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.

This decision was based on trial results showing that Enhertu reduced the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.

Enhertu has been jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Co.



Write to Jaime Llinares Taboada at [e-mail]; @JaimeLlinaresT



(END) Dow Jones Newswires

June 27, 2022 02:40 ET (06:40 GMT)

[gibbs1] 23/6/2022 16:05

AstraZeneca's Wilson disease treatment shows promise in phase 3 trials

Thu, 23rd Jun 2022 15:59
Alliance News

(Alliance News) - AstraZeneca PLC on Thursday reported strong results

from phase III clinical trials for ALXN1840.

The Cambridge-based pharmaceutical company said the FoCus phase III trial of its once-daily, investigational oral medicine

ALXN1840 met its primary endpoint in the treatment of Wilson disease.

Wilson disease is an inherited condition which results in excess copper levels in the liver, brain and other organs. This leads to damage which can greatly impact those with the disease.

ALXN1840 showed copper mobilisation from tissues three-times greater than the standard of care arm.

Patients

experienced rapid copper mobilisation, with a response at four weeks, which was sustained through 48 weeks.

ALXN1840 is a novel molecule designed to bind to copper and remove it from the body's tissue and blood.

Shares in AZ were up 0.6% to 10,368.00 pence each in London on Thursday afternoon.

Two mechanistic trials in Wilson disease are underway, and AZ's rare disease group Alexion is working with global health authorities to submit the data for review.

By Elizabeth Winter; [e-mail]

[buywell3] 22/6/2022 07:33

Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom